The tablets are for distribution in low and middle-income nations. The Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg fixed-dose combo is intended for the treatment of human immunodeficiency ...

Patients who were receiving abacavir at study entry had elevated baseline levels of some inflammatory biomarkers. During the course of the study, current abacavir use was associated with higher ...